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This paper reports on an innovation, within a maternity unit, to introduce a 
fetal fibronectin, point of care test, that will aid the clinician in correctly 
diagnosing preterm labour. In turn this will assist in developing an individual 
plan of care for each woman with suspected preterm labour, rather than 
treating each case with the same interventions regardless of subsequent 
outcomes.  
 
Fetal fibronectin (fFN) is a complex adhesive glycoprotein which can be 
detected in the cervicovaginal secretions of women during pregnancy. Its 
concentration varies throughout pregnancy, detectable before 24 weeks of 
pregnancy the concentration then dips below the minimum detectable level up 
to 34 weeks of pregnancy, unless the woman is in preterm labour.  
 
The fFN test was successfully introduced into clinical practice. Demonstrating 
that when used appropriately, on women with symptomatic suspected preterm 
labour, fFN testing can aid in accurate diagnosis and thereby avoid 








 The majority of women (80%) who present with the signs and 
symptoms of preterm labour will go on to deliver at, or after, 37 weeks 
gestation (Morgan et al 2007) 
 
 Interventions and treatments for this group of women can therefore be 
unnecessary and costly. 
 
 Fetal Fibronectin (fFN) is a complex adhesive glycoprotein which can 
be detected in the cervicovaginal secretions during pregnancy. 
 
 A negative fFN test is 99.2% predictive that the woman will not deliver 
in the next 14 days (Honest.et al 2002) 
 
 The introduction of a safe, simple fFN test can assist in correctly 












Preterm birth is defined by the World Health Organisation as birth between 20 
and 36 + 6/7 weeks of gestation (Berghella, Hayes, Visintine & Baxter, 2008) 
and is responsible for the majority of perinatal morbidity and mortality in the 
United Kingdom (Lu, Goldenberg, Cliver, Kreaden & Andrews, 2001).  
 
Prior to the introduction of fFN testing the management of suspected preterm 
labour in this Trust was hospital inpatient admission, tocolytic therapy and 
selective in-utero transfers (Local Trust Guidelines, 2008). In approximately 
20% of these admissions the woman will be found to be in labour and 
subsequently deliver a premature baby. The majority (80%) of women with the 
signs and symptoms of preterm labour will deliver at or after 37 weeks 
gestation. This means that many of the inpatient admissions, treatments and 
transfers, for suspected preterm labour are unnecessary and costly (Morgan, 
Goldenberg & Schulkin, 2007). 
 
Previous practice was therefore expensive and highly disruptive to the woman 
and her family as it requires admission, observation with treatment and/or in-
utero transfer of mother (Honest, Bachmann, Gupta, Kleijnen & Khan, 2002).  
It is therefore essential to identify as early as possible the 20% of women in 
true preterm labour, so that they can be treated appropriately, and the 80% 





AIM OF THE INNOVATION 
 The aim of this innovation was; to introduce a safe simple (fFN) test to assist 
in correctly diagnosing true preterm labour, which will; 
 Enable clinicians to appropriately treat each woman (Grobman, 
Welshman & Calhoun, 2004). 
 Reduce the risks associated with preterm. (Lu et al., 2001).  
 Reduce unnecessary intervention. (Berghella et al, 2008). 
 Minimise the hospital stay. (Ness, Visintine, Ricci & Berghella, 2007). 
 Reduce anxiety in this group of women (Anderson, 2000). 
 Reduce costs of treatment surrounding preterm labour (Grobman et al., 
2004). 
In symptomatic women who are fFN negative, the risk of delivery within 14 
days is 0.8%, whereas the risk in fFN positive women is 14% (Honest et al., 
2002). A Point of Care Test (POCT) for cervicovaginal fFN before steroids, 
tocolysis and in-utero transfer would reduce the in-utero transfer rate by 
approximately 50% without any significant adverse effect, as well as 
decreasing the unnecessary use of tocolysis and steroids (Honest et al., 
2002). Cervicovaginal fFN can be assessed using a simple POCT and the aim 
of this innovation is to implement this safe and effective test into clinical 
practice. 
 
APPRAISAL OF THE FETAL FIBRONECTIN LITERATURE 
The highest level of literature found in this appraisal was a 2008 Cochrane 
Systematic Review by Berghella et al; this was appraised using Critical 
Appraisal Skills Programme (CASP). The criteria used for considering studies 
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for inclusion in the systematic review were published randomized controlled 
trials; the participants were pregnant women between the gestational ages of 
22 to 34 weeks, who were screened for fFN, when presenting with the signs 
and symptoms of preterm labour.  
 
Although 13 trials were identified by Berghella et al (2008) only 5 were eligible 
for inclusion because in the remaining 8 only women with positive results were 
included, this excluded women with a negative result and therefore was 
thought to bias the trial. Although only trials with both positive and negative 
results were included in the review, the focus of the Berghella et al systematic 
review (2008) was to assess the effectiveness of management, based on the 
knowledge of positive fFN test results.  Thus he ignored the value of the 
negative result, losing the opportunity to widen the scope of the review to 
demonstrate the usefulness of the negative result in the clinical field.  The 
focus of this literature review and of the innovation is in predicting the 
symptomatic woman that will not go on to deliver prematurely. The more 
important result, to this innovation, is the negative fFN and the effect that this 
has on preventing unnecessary interventions (Peaceman et al, 1997).  It was 
difficult, therefore, to make any meaningful comparisons between the trials 
and the proposed innovation as the women with negative results were not 
followed up in the trials.  The systematic review did nevertheless demonstrate 
sound evidence of the accuracy of the fFN test, and its relevance to predicting 
delivery in women presenting with suspected preterm labour, thereby clearly 
establishing the need for the implementation of this innovation. There was 
also no mention in the literature reviewed of the incident of false positive fFN 
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tests, this potential problem will be looked at carefully when evaluating the 
introduction of fFN tests in this innovation.  
 
IMPLEMENTATION 
Managing the implementation of this innovation proved more complex than 
first anticipated as it involved organisational, individual and team change.   
Any innovation should be driven by senior leadership (Clarke, 2008) with 
commitment to providing adequate resources. It is especially important here 
as changing practice requires a change in organisational culture and attitudes 
and this is unlikely to be achieved if senior leadership is not involved (Clarke, 
2008).  Engaging the Lead Consultant of Delivery Suite, General Manager 
and Head of Midwifery was essential to the success of this innovation.  It 
would not only secure the necessary finances, but would also give credence 
to the test itself and the value of change in clinical practice.  Involvement of 
senior management was achieved by all members of the team presenting the 
literature search and initial financial projection. The importance of this support 
cannot be underestimated as leadership actions, such as supporting the 
innovation, strongly influence peoples beliefs (Blackwood, 2006). 
  
 When forming the implementation team the aim was to keep the membership 
numbers to a minimum (Cohen & Bailey, 1997) as the more people in a team, 
the more difficult it is to communicate quickly and effectively, to achieve 
consensus and coordinate activity. This team would need to steer and co-
ordinate, as well as review the process and evaluate the outcomes. The team 
members were initially selected by the team leader approaching individuals in 
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the appropriate areas. After the first month interest in the project was such 
that midwives, doctors and students volunteered to be involved, strengthening 
the support for the innovation. The original SWOT Analysis completed at the 
inception of the innovation was looked at again and expanded (Table 1.1).  
 
Table 1.1. 
SWOT Analysis 2 
STRENGTHS 
 
 Simple Point of Care Test 
 No extra invasion to women 





 Unknown false positive % 
 Finding time for training 
 Non compliance of staff 
OPPORTUNITIES 
 
 Improved experience for 
women 
 Intervention reduced 
 Intervention focused on 
most high risk cases 






 Approval by POCT committee 
 Securing finance 
 Multi-disciplinary teams 
variability in using test 
 
From this targets were identified and the innovation was divided into five 
areas with individual members of the team volunteering to be responsible to 
drive forward one area. These were; 
 Business case and securing finance 
 Sourcing the test. 
 Presenting to the POCT committee 
 Writing guideline/policy 
 Training 
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Over arching all of these and the responsibility of all members of the team 
was communication of the innovation to the multi-disciplinary team. 
Many different stakeholders would be involved in the implementation of this 
innovation, who work in two very different area’s, the Maternity Assessment 
Centre (MAC) and Delivery Suite (DS). The teams focus was, in keeping with 
the Trusts philosophy, to make patient safety and quality of care strategic 
priorities. Therefore obtaining the right test was imperative to the success of 
the innovation (Peaceman et al., 1997). The test chosen by the majority of the 
team had all the quality assurance that would be required by the POCT 
committee. As well as being simple to use, the company would also provide a 
training and audit package to assist the team in these areas.  The literature 
was also very ‘user friendly’ and would be a useful aid in the training and 
preparation of local guidelines for the use of the test.  
 
The test was then presented to and approved by the Point of Care Test 
Committee and needed to conform to the POCT policy. To facilitate writing a 
local guideline to underpin the introduction of the fFN test the team contacted 
six other Trusts who had already introduced the test. Appreciation of the 
importance of sharing information (Lynch, 2006) proved invaluable as 
problems that they had encountered during the implementation of fFN testing 
in their areas was highlighted. Advice was given by the fFN leads in each 
Trust on the writing of the guideline and the content of the training 
programme. The finished guideline is a sound reflection of the best available 
evidence for safe effective practice in this area and a testament to inter-Trust 
sharing.  Clinical champions were appointed to increase wider motivation to 
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succeed by maintaining the enthusiasm for the project in the clinical area, 
throughout the 24 hour period (Stuart, 2003), as women can present at 
anytime in preterm labour, this would ensure that the test did not become a 
Monday to Friday, 9 to 5 innovation.  
 
The first problem encountered was a clinical one. The swab must be taken 
before any other examination is performed, so that the accuracy of the test is 
not compromised by other products such as lubricants, used during vaginal 
examination. Therefore the swab could not be taken as an after thought, when 
the practitioner was reminded by the midwifery team. This problem was 
minimised through constant reminders from the implementation team and the 
clinical champions in the initial stages until the test became established. It was 
noted though that the midwifery team took more of a lead in the innovation, 
often having to remind the medical staff that the criteria for taking the test had 
been met and reminding them of the guideline.  This can be explained, in 
some part, by the rapid turnover of junior medical staff (four monthly rotations 
for General Practitioner Trainees) and the seniority of the MAC and DS Co-
ordinators. Yet a midwife taking the lead, in instructing junior doctors, as 
demonstrated in this innovation, has been part of Maternity Units hierarchy for 
years (Cartwright 1979).  
The second problem was the need to compete with the day to day clinical 
work which meant that the vision of this innovation needed to be 
communicated frequently. This was solved by attendance of the team at multi-
disciplinary handover’s between shifts, enabling the testing to be discussed 
three times a day. At the same time results were fed back, any problems 
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highlighted and most importantly any member of staff that had not been 
trained could be identified.  Communicating in this way had the added bonus 
of ‘creating short term wins’ (Kotter, 1995) as when results were fed back to 
the multi-disciplinary team in this way, women who had benefited from a 
negative fFN test, by being reassured and sent home were highlighted.  
Success stories like these reinforced the usefulness of the test and the vision 




The fetal fibronectin test was a completely new concept in this Trust therefore 
the level of knowledge regarding what fFN is and its uses at the start of this 
innovation was minimal to non existent. A lot of new information needed to be 
delivered and understood by the multi-disciplinary team in a short space of 
time. Evaluation of the effectiveness of the dissemination of information was 
by feedback from staff once the training had been completed (Stuart, 2003). A 
simple form indicating their level of knowledge prior to training and following 
the session was filled in. This confirmed that 100% of staff felt their knowledge 
had increased following the training. Feedback from the team members at the 
end of the three month period was very positive and the enthusiasm for the 
project remained high.  
 
Introducing this test as a POCT rather than a laboratory based test has meant 
rapid results were received by the clinical team (Grobman et al., 2004). The 
machine and printer were provided and maintained  free from the company. 
The value of the internal quality control of the device, that determined it was 
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technically performing correctly, was confirmed by the reliability of the results 
obtained.  The device proved to be very user friendly. All clinicians completed 
a feedback sheet at the end of the data collection period to audit the POCT. 
100% reported that no problems were found with the device or printer.  Also 
reported was the ease of the daily quality control test and the clear printout 
that was received containing results, date and time. The results were obtained 
within 20 minutes of the swab being taken; therefore rapid decisions could be 
made on plans of care reducing the overall anxiety of the women (Kirkham, 
2004). 
 
An unanticipated success of the innovation was the involvement of student 
midwives and medical students. Both these groups were enthusiastic from the 
start, therefore becoming involved early on.  The clinical setting provides 
unique learning experiences for students, which if managed proactively can 
be a positive growing episode (Stuart, 2003).   Being involved in the 
implementation of an innovation and following the change process was an 
experience that the students had not been exposed to.  Two of the student 
midwives reflected on their experience and shared there reflection with their 
peers at University.  This meant that the innovation was taken to a much wider 
audience than was anticipated, as the group came from many surrounding 








In terms of clinical outcome the success of the innovation, was to identify 
women who presenting with the signs and symptoms of preterm labour would 
deliver prematurely. Use of the fFN test was to determine which of these 
women were not likely to deliver in the next 14 days.  This would in turn 
prevent unnecessary intervention and reduce anxiety (Kirkham, 2004) and 
allow appropriate intervention for the women who were likely to deliver, thus 
also saving on financial resources.  As this was not a primary research 
project, clinical audit was used to evaluate the effectiveness of the test itself. 
Each test was recorded not only in the woman’s records but also in a project 
book. This information was then entered on to a data base specifically set up 
for the project. 
 
During the data collection time, 1/1/09 to 31/3/09, 32 tests were performed. 
The number of women presenting with threatened preterm labour each year is 
approximately 398 (Local Annual Maternity Statistics, 07/08) therefore it would 
be expected that approximately 100 women would present during the data 
collection time with symptoms, in fact 91 presented. Of these women a large 
proportion would be excluded from having the test. This is for three reasons; 
 The test was not appropriate in women with symptoms of cervical 
dilatation >3cm, bleeding per vagina (PV), spontaneous rupture of 
membranes (SRM) (Ness et al, 2007). These women will inevitably go 
on to deliver prematurely (Chandiramani & Shennan, 2006).  
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 The fFN test sample must be collected before the performance of any 
activities or procedures which might disrupt the cervix e.g. coitus, 
digital examination, vaginal ultra sound (Stafford et al., 2008) 
 Tests result would be invalid if the swab was contaminated by any 
lubricants, soaps or disinfectants (Stafford et al., 2008). 
At the start of the innovation it was difficult to predict how big the excluded 
group might be as it depended on so many variables.  In particular the 
accurate giving and taking of the woman’s history (Grobman et al., 2004). This 
was discussed at the weekly implementation team meeting and an estimate, 
based on clinical experience, was thought to be approximately 30% of all 
women presenting would be excluded from the test.  In fact following the data 


















Uptake of tests. 
 
A partial explanation for this high figure was that the uptake of the test was 
lower than expected in the first month (20% compared to 41.3% and 43.7% in 
the following months). This was thought to be the clinicians not remembering 
to perform the test at the start of the examination, as communications 
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improved regarding the innovation then so did the uptake. The number of 
tests performed overall correlates with expectations reassuring the team that 
the test was being used appropriately. 
 
The negative and positive results were entered on to the data base separately 
so that a clear picture could be seen regarding the outcomes. At the end of 
the data collection period the women’s records were all recalled so that the 
treatment received and the outcomes could be added to the data base. The 
results of the tests were analysed separately (Figures 1.3 & 1.4). From this we 
could see how the result of the test correlated with the outcomes and whether 
clinical interventions were appropriate  
 
Figure 1.3 Negative tests 




























Time Elapsed (Day's) After Positive FFN Test Target Sucsess Line (Day's)
 




NEGATIVE TEST OUTCOMES 
As can be seen in Figure 1.3 all the women with negative tests did not deliver 
within the 14 day period, which equates to 100% accuracy. Of the 27 negative 
tests obtained the clinical records were audited to ascertain what decisions 
had been made regarding a plan of care for each woman. Only 4 (14.8%) of 
the women who tested fFN negative were admitted for observation, of these 
only one was given steroids and none were given tocolytic therapy. The 
reasons for the admissions had been documented in all cases as 
abnormalities in the cardio tocograph recording (CTG) of the fetal heart. This 
meant that the women were admitted for reasons other than the suspected 
preterm labour; therefore the negative fFN test remained relevant. 
 
The concern that there would be a high percentage of false positive results 
proved to be wrong.  Out of the five positive tests obtained all delivered within 
14 days, following treatment to delay delivery, so that time for corticosteroid 
therapy to work was achieved (Chandiramani & Shennan, 2006). 
 
COST ANALYSIS   
The cost of each test during the first three months was £35.  This was a 
reduced rate (from £45) negotiated for the trial period and an increase in price 
would have to be taken into account when assessing whether the innovation 




No tocolytic therapy (Atosiban) was used in any of the 27 negative tests.  The 
cost of Atosiban treatment for one woman is £386 (information obtained from 
pharmacy budget information), saving £10,422.  
 
An ante-natal in patient stay for a period of 72 hours is approximately £425.30 
(information from Trust finance department). 23 women were not admitted 
following a negative test, saving £9,781.90. 
 
The implementation of the innovation and the training was undertaken within 
the regular clinical shifts of the multi-disciplinary team.  The training itself took 
30 minutes and took place in the clinical field and therefore, though not 
measurable, was not a cost implication of any great amount. Although the 
staff were taken away from other duties for that short period no extra shifts 
were booked to cover this time away from the clinical area. 
   Cost of tests = £1120 
  Cost of intervention and admission if test not used = £20,203.90 
  Saving to Trust (Jan/Mar 09) = £19,083.90 
Since the inception of the innovation subsequent data has been analysed and 
audits of results in the periods of July 09 to September 09 and again in 
January 10 to March 10 have confirmed the original findings. 
 
CONCLUSION 
This project was seen as a small change in a busy clinical area, but the 
amount of work that it would need to drive it forward was underestimated at 
the start. Getting the balance right between the short term goal of introducing 
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the test, and the long term goal of the education/training of the clinical staff, 
enabling them to take ownership and take forward the innovation, was difficult 
(Bridges, 2003). On reflection, the first month of data collection was 
disappointing, as previously noted this could have been prevented by more 
time being allocated to the initial training of staff and better communication of 
the purpose of the test.  
 
Introducing a POCT into the clinical area also proved to be problematic, as it 
was much more time consuming than first anticipated and completely threw 
our carefully planned timetable adrift.  This happened because none of the 
implementation team had any prior knowledge of the processes involved, 
therefore initially no extra time was factored in to compensate for this.   
 
RECOMMENDATIONS FOR PRACTICE/FURTHER RESEARCH 
Despite extensive research the incidence of preterm birth is increasing in 
many countries (Berghella et al., 2008).  All members of the family in which 
preterm birth occurs feel the medical, social, psychological and financial 
effects (Lumley, 2004). 
 
This innovation was driven by the need to accurately predict whether a 
woman with symptoms is indeed actually in preterm labour. To be able to do 
this means that the clinical team can either prevent unnecessary interventions 
or quickly put in place necessary interventions. This in turn reduces morbidity 
and mortality in mother, baby and the family (Grobman et al., 2004, 
Chandiramani & Shennan, 2006).  To this end the fetal fibronectin test has 
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been demonstrated, by this project, to be a very useful point of care test, 
which enhances the decision making of the multi-disciplinary team. 
 
The use of the fFN test in future practice could be expanded to include women 
with a high risk of preterm labour i.e. previous history or multiple pregnancies 
who are asymptomatic.  At present these high risk women often spend a large 
part of their pregnancy as an inpatient for observation/rest ‘just in case’ they 
show signs of going into labour (Chandiramani & Shennan 2006).  A test 
performed every month between 23 to 34 weeks gestation could indicate 
whether an asymptomatic woman was in danger of going into labour and 
provide more time for treatment to successfully prevent this occurring.  As a 
simple POCT this could be performed at the local health centre, during routine 
antenatal clinics, therefore causing little disruption to the woman and her 
family (Kirkham, 2004).  
 
Further research is required to determine whether the use of the fFN test on 
asymptomatic women would reduce the incidence of preterm delivery in high 
risk women. No trials were identified during the literature search on women 
without signs or symptoms of labour being routinely tested for the presence of 
fetal fibronectin.  Women’s choice and experience would also need to be 
measured, to determine how they feel about investigations and interventions 
surrounding preterm labour and delivery (Kirkham, 2004). Maternity care has 
moved on in recent years and now the more complicated notion of informed 
choice has replaced simple consent to treatment’s (Kirkham, 2004). Evidence 
in the literature goes back as far as 1979 (Cartwright, 1979) to show that 
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women want to be consulted and informed regarding the treatments they 
receive during pregnancy and labour. Therefore measuring their experiences 
of an innovation such as this is an important part of the long term evaluation 
process (Kirkham, 2004). 
 
 This innovation in clinical practice has been of great benefit to the multi-
disciplinary team, the maternity unit, the Trust and most importantly to the 
women and their families.  The change process has not been without its 
problems, but these have been identified and solved in a positive way by the 
implementation team. Evaluation of the data to date is very positive and the 
aim of the innovation, to assist in correctly diagnosing true preterm labour, has 
been met.  All stakeholders have shown ownership and commitment to the 
change which is now becoming embedded within the clinical practice of this 
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